CD8A and neoplasm: The combination of cytotoxic agents and bevacizumab in colorectal cancer could enhance the efficacy of immune drugs by increasing neoantigen exposure, especially with highly active chemotherapy regimens, inducing immune-mediated cell death, increasing tumor lymphocyte infiltration CD8+ T cells and reducing tumor-associated myeloid-derived suppressor cells.